MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Core Viewpoint - MIRA Pharmaceuticals, Inc. has announced positive results for its oral drug candidate Ketamir-2, which has shown efficacy in restoring normalized behavior in stressed animals within a validated model of post-traumatic stress disorder (PTSD) [1] Group 1: Drug Development - Ketamir-2 is currently undergoing evaluation in an ongoing Phase 1 clinical trial specifically for neuropathic pain, where it has demonstrated a favorable safety profile to date [1] - The company is broadening the development of Ketamir-2 into neuropsychiatric disorders, including PTSD, indicating a strategic expansion of its therapeutic applications [1] Group 2: Company Overview - MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders [1]